The abstract is read at the publisher; the summary is JClub's.
In a real-world cohort of 265 U.S. patients with small cell lung cancer, tarlatamab achieved a 52.6% disease control rate and median rw-PFS of 2.3 months.
- Why it matters: Real-world efficacy and safety for tarlatamab in small cell lung cancer are limited, especially regarding outcomes and neurologic toxicity in patients with brain metastases.
- What they did: This retrospective ONWARD-SCLC consortium study (11/2023–4/2025) evaluated clinical outcomes and toxicities, including CRS and ICANS, and assessed prophylactic medication effects.
- The result: After Cycle 1 Day 1, CRS occurred in 40.8% (grade 3–4: 3.8%) and ICANS in 21.5% (grade 3–4: 6%); prophylactic tocilizumab was linked to lower CRS and ICANS versus no prophylaxis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.